Dyadic to Present at Upcoming Events
May 03 2021 - 8:30AM
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:
DYAI) a global biotechnology company focused on further improving,
applying and deploying its proprietary C1-cell protein production
platform to accelerate development, lower production costs and
improve the performance of biologic vaccines and drugs at flexible
commercial scales, today announced that the Company will
participate in the following upcoming events:
KOL Fireside Chat Title: The Potential of the
Transformative Dyadic C1 Protein Technology in Helping Meet Global
Health ChallengesTime: Tuesday, May 4, 2021 10:00 AM Eastern
Time
The conversation will be moderated by Dr. David
Bramhill, a veteran in the biotechnology industry with extensive
experience using a wide array of protein production
technologies.
The discussion will include the following Key
Opinion Leaders (KOLs):
- Alain Townsend, Ph.D. – Weatherall
Institute - Oxford University
- Albert Osterhaus, P.V.M, Ph.D. –
Erasmus Medical Centre
- Cecil Nick – Parexel (Clinical
& Regulatory Support)
- Joris Vandeputte – International
Alliance for Biological Standardization
World Vaccine CongressPresenter: Mark Emalfarb,
CEOEvent Link:
https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm
Track: COVID-19 Vaccine Response & ApproachesTitle: Dyadic
C1-Cells - Flexible Scale Manufacturing of NexGen MonoValent &
MultiValent Recombinant Antigen Vaccines & AntibodiesTime:
Tuesday, May 4, 2021 4:30 PM to 4:45 PM Eastern Time
Track: COVID-19 Trials & Infectious DiseasesTitle: DYADIC
C1-CELLS - Realizing Full Global Potential of MonoValent and/or
MultiValent Recombinant Antigen Vaccines & AntibodiesTime:
Wednesday, May 5, 2021 5:00 PM to 5:15 PM Eastern Time
Track: COVID-19 Manufacture & SupplyTitle: Dyadic C1- Cells,
industrially proven hyper productive thermophilic filamentous
fungus for manufacturing safe, effective and affordable recombinant
protein antigen vaccines & antibodies for world populationTime:
Thursday, May 6, 2021 3:30 PM to 3:45 PM Eastern Time
17th Annual PEGS
BostonPresenter: Mark Emalfarb, CEO Track: Accelerating
Vaccine Development for COVID-19 Title: Making Vaccines in Large
Quantities, Flexible Commercial Scales More Affordable - C1
CellsTime: Thursday May 13, 2021 2:40 PM -3:00 PM Eastern TimeEvent
Link: https://www.pegsummit.com/
Dyadic Management will be available during the
events for one-one-one meetings. Interested industry partners may
request a one-on-one meeting at jlatiuk@dyadic.com or
contact Dyadic at (561) 743-8333. If you are registered for any of
the events, you can also request a meeting through the event
platform.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical protein production
platform based on the fungus Thermothelomyces heterothallica
(formerly Myceliophthora thermophila), named C1. The C1
microorganism, which enables the development and large-scale
manufacture of low cost proteins, has the potential to be further
developed into a safe and efficient expression system that may help
speed up the development, lower production costs and improve the
performance of biologic vaccines and drugs at flexible commercial
scales. Dyadic is using the C1 technology and other technologies to
conduct research, development and commercial activities for the
development and manufacturing of human and animal vaccines and
drugs, such as virus like particles (VLPs) and antigens, monoclonal
antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars
and/or biobetters, and other therapeutic proteins. Certain other
research activities are ongoing which include the exploration of
using C1 to develop and produce certain metabolites and other
biologic products. Dyadic pursues research and development
collaborations, licensing arrangements and other commercial
opportunities with its partners and collaborators to leverage the
value and benefits of these technologies in development and
manufacture of biopharmaceuticals. In particular, as the aging
population grows in developed and undeveloped countries, Dyadic
believes the C1 technology may help bring biologic vaccines, drugs
and other biologic products to market faster, in greater volumes,
at lower cost, and with new properties to drug developers and
manufacturers, and improve access and cost to patients and the
healthcare system, but most importantly save lives.
Please visit Dyadic’s website at http://www.dyadic.com/ for
additional information, including details regarding Dyadic’s plans
for its biopharmaceutical business.
Contact:
Dyadic International, Inc.Mark Emalfarb,
CEOPhone: (561) 743-8333Email: memalfarb@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024